EP1663226A1 - Compositions pharmaceutiques a base de moxifloxacine et leurs procedes de preparation - Google Patents

Compositions pharmaceutiques a base de moxifloxacine et leurs procedes de preparation

Info

Publication number
EP1663226A1
EP1663226A1 EP04769278A EP04769278A EP1663226A1 EP 1663226 A1 EP1663226 A1 EP 1663226A1 EP 04769278 A EP04769278 A EP 04769278A EP 04769278 A EP04769278 A EP 04769278A EP 1663226 A1 EP1663226 A1 EP 1663226A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
water insoluble
substantially water
insoluble excipient
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04769278A
Other languages
German (de)
English (en)
Inventor
Romi Barat Singh
Pananchukunnath Manoj Kumar
Vishnubhotla Nagaprasad
Sanjeev Kumar Sethi
Rajiv Malik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1663226A1 publication Critical patent/EP1663226A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • moxifloxacin is l-cyclopropyl-7- ([S, S]-2,8-diazabicyclo [4.3. 0] non-8-yl)-6-fluoro-l, 4-dihydro-8-methoxy-4-oxo-3-quinolonecarboxylic acid. It is an antiinfective agent and is known from U.S. Patent No. 4,990,517.
  • Moxifloxacin can be used for the treatment of various infections, like acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and community acquired pneumonia.
  • U.S. Patent No. 4,990,517 discloses a pharmaceutical preparation that includes the active compound, with microcrystalline cellulose, maize starch, poly- (l-vinyl)-2- pyrrolidone (insoluble), finely divided silica and magnesium stearate.
  • U.S. Patent No. 5,286,754 discloses pharmaceutical formulations of ciprofloxacin that include binder based on cellulose, disintegrant based on starch, and a disintegrant based on cellulose derivatives and/or cross-linked polyvinylpyrrolidones.
  • Patent No. 6,610,327 discloses pharmaceutical preparations for oral administration that includes moxifloxacin or a salt or solvate/hydrate thereof, at least one dry binder, at least one disintegrant and at least one lubricant, characterized in that the preparation contains 2.5 % to 25% of lactose.
  • the inventors have surprisingly found that bioequivalent formulations to commercially available Avelox tablet formulations can be obtained by mtragranular and extragranular distribution of substantially water insoluble pharmaceutical excipients. Summary of the Invention In one general aspect there is provided a pharmaceutical composition that includes moxifloxacin and at least one mtragranular and extragranular substantially water insoluble excipient.
  • Embodiments of the composition may include one or more of the following features.
  • the composition may further include other pharmaceutically accepted excipients.
  • the other excipients may include one or more of binders, disintegerants, fillers, lubricants/glidants, and colorants.
  • the substantially insoluble excipients may include one or more of microcrystalline cellulose, pregelatinized starch, dicalcium phosphate dibasic, corn starch, and the like.
  • the binders may be one or more of polyvinyl pyrrolidone, hydroxypropyl cellulose and gums.
  • the fillers may be one or more of cellulose derivatives, starch derivatives, sugars, sugar alcohols, and the like.
  • the disintegrant may be one or more of pregelatinized starch, cross-linked polyvinylpyrrolidone and sodium croscarmellose sodium. In particular, the disintegrant maybe croscarmellose sodium. The disintegrant maybe from 0.5 to 10% by weight of the composition. More particularly, it may be from 2 to 5% by weight of the composition.
  • the lubricant or glidant may be one or more of fatty acids and their salts, colloidal silicon dioxide and talc. In particular, the lubricant is magnesium stearate and the glidant is colloidal silicon dioxide.
  • the lubricant may be advantageously employed in an amount of from 0.05 to 3.0% by weight of the composition. More particularly, it may be from 0.2 to 2% by weight of the composition.
  • the composition may be formulated in the form of granules filled in capsule, tablet or other suitable oral dosage form and, in particular, may be a tablet.
  • the tablet formulation may further be coated.
  • a process for preparing a pharmaceutical composition of moxifloxacin includes a) preparing an mtragranular portion by mixing moxifloxacin and at least one substantially water insoluble excipient; b) preparing an extragranular portion by mixing at least one substantially water insoluble excipient and other pharmaceutically accepted excipients; and c) compressing said mtragranular portion and extragranular portion to a tablet or filling said mtragranular portion and extragranular portion into a capsule.
  • Embodiments of the process may include one or more of the following features.
  • the mtragranular portion may further include other pharmaceutically accepted excipients.
  • the other excipients may include one or more of binders, disintegerants, fillers, lubricants/glidants, and colorants.
  • the substantially insoluble excipients may include one or more of microcrystalline cellulose, pregelatinized starch, dicalcium phosphate dibasic, corn starch, and the like.
  • the binders may be one or more of polyvinyl pyrrolidone, hydroxypropyl cellulose and gums.
  • the fillers may be one or more of cellulose derivatives, starch derivatives, sugars, sugar alcohols, and the like.
  • the disintegrant may be one or more of pregelatinized starch, cross-linked polyvinylpyrrolidone and sodium croscarmellose sodium. In particular, the disintegrant maybe croscarmellose sodium. The disintegrant maybe from 0.5 to 10% by weight of the composition. More particularly, it may be from 2 to 5% by weight of the composition.
  • the lubricant or glidant may be one or more of fatty acids and their salts, colloidal silicon dioxide and talc. In particular, the lubricant is magnesium stearate and the glidant is colloidal silicon dioxide.
  • the lubricant may be advantageously employed in an amount of from 0.05 to 3.0% by weight of the composition. More particularly, it may be from 0.2 to 2% by weight of the composition.
  • Avelox tablet formulations can be obtained by mtragranular and extragranular distribution of substantially water insoluble pharmaceutical excipients, with or without the inclusion of lactose.
  • the formulation maybe in the form of granules filled in capsule, tablet or other suitable oral dosage form.
  • moxifloxacin refers its free base, salts, solvates, enantiomers or mixtures thereof.
  • the salts of moxifloxacin include, for example, acid addition salts, such as salts of hydrochloric acid, sulphuric acid, acetic acid, lactic acid, etc., and also salts with bases, such as sodium hydroxide, potassium hydroxide, etc. hi particular, the acid addition salt may be moxifloxacin hydrochloride monohydrate.
  • acid addition salt may be moxifloxacin hydrochloride monohydrate.
  • substantially insoluble refers to the solubility less than that of lactose.
  • substantially insoluble excipients include microcrystalline cellulose, pregelatinized starch, dicalcium phosphate dibasic, corn starch, and the like.
  • the mtragranular and extragranular portions may also contain other pharmaceutically acceptable excipients such as binders, disintegerants, fillers, lubricants/glidants, colorants, and the like.
  • Suitable binders may include one or more of polyvinyl pyrrolidone, hydroxypropyl cellulose, gums and the like.
  • Suitable fillers may include one or more of cellulose derivatives, starch derivatives, sugars, sugar alcohols and the like.
  • Suitable disintegrants include one or more of pregelatinized starch, cross-linked polyvinylpyrrolidone, sodium croscarmellose sodium and the like. In particular, the disintegrant may be croscarmellose sodium.
  • the pharmaceutical composition may contain from 0.5 to 10%, preferably from 2 to 5%, of the disintegrant.
  • Suitable lubricants and glidants may include one or more of fatty acids and their salts, colloidal silicon dioxide, talc and the like.
  • the lubricant is a salt of a fatty acid, for example, magnesium stearate.
  • the glidant is colloidal silicon dioxide.
  • the lubricant is advantageously employed in an amount of from 0.05 to 3.0%, for example, 0.2 to 2%.
  • the colors maybe selected from any FDA approved colors for internal use.
  • the formulation may optionally be coated.
  • the dosage form may be in tablet or capsule form, however, the tablet form is particularly suitable.
  • the tablet may further be coated.
  • any formulation which is customary in pharmaceutical technology, such as, for example, those based on hydroxypropyl methyl cellulose (HPMC) and/or polyethylene glycol of various molecular weights may be used.
  • HPMC hydroxypropyl methyl cellulose
  • polyethylene glycol of various molecular weights
  • the formulations prepared according to the present invention were found to be bioeqivalent to the Avelox tablet dosage form available in the US market by Bayer.
  • the following data shows the phannacokinetic data of tablet formulation of present invention and Avelox tablet available in US market carried out in 12 healthy human volunteers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte à des compositions pharmaceutiques à base de moxifloxacine, ainsi qu'à des procédés de préparation de ces compositions.
EP04769278A 2003-09-03 2004-09-03 Compositions pharmaceutiques a base de moxifloxacine et leurs procedes de preparation Withdrawn EP1663226A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1099DE2003 2003-09-03
PCT/IB2004/002875 WO2005020998A1 (fr) 2003-09-03 2004-09-03 Compositions pharmaceutiques a base de moxifloxacine et leurs procedes de preparation

Publications (1)

Publication Number Publication Date
EP1663226A1 true EP1663226A1 (fr) 2006-06-07

Family

ID=34259939

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04769278A Withdrawn EP1663226A1 (fr) 2003-09-03 2004-09-03 Compositions pharmaceutiques a base de moxifloxacine et leurs procedes de preparation

Country Status (3)

Country Link
EP (1) EP1663226A1 (fr)
WO (1) WO2005020998A1 (fr)
ZA (1) ZA200602497B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
CN100363001C (zh) * 2005-09-21 2008-01-23 深圳市天一时科技开发有限公司 一种莫西沙星胶囊剂及其制备方法
WO2009135646A2 (fr) * 2008-05-05 2009-11-12 Farmaprojects, Sa Compositions pharmaceutiques stables et procédés de préparation desdites compositions adaptés à l’échelle industrielle
WO2010066385A1 (fr) 2008-12-08 2010-06-17 Ratiopharm Gmbh Moxifloxacine compactée
CN102247313A (zh) * 2010-06-11 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服缓释固体制剂
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
GR1008169B (el) * 2013-03-19 2014-04-08 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον εναν αντιβακτηριακο παραγοντα φθοριοκινολονης και μεθοδος για την παρασκευη αυτου
CN104622821B (zh) * 2013-11-13 2018-04-10 武汉先路医药科技有限公司 解决溶出行为受制粒时间影响问题的莫西沙星片剂配方
CN106074413A (zh) * 2016-07-20 2016-11-09 南通雅本化学有限公司 一种含有莫西沙星的药物组合物
CN109045034B (zh) * 2018-09-29 2021-04-13 哈尔滨珍宝制药有限公司 一种盐酸莫西沙星药物组合物及其制备方法和应用
EP4164645A4 (fr) * 2020-06-15 2024-07-10 The Global Alliance For Tb Drug Dev Inc Composition antibactérienne combinée et procédé de thérapie antibactérienne
EP4164626A4 (fr) * 2020-06-15 2024-07-03 Mylan Laboratories Ltd Composition antibactérienne polythérapeutique et méthode de thérapie antibactérienne

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
HU229065B1 (en) * 1998-11-10 2013-07-29 Bayer Ip Gmbh Pharmaceutical moxifloxacin compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005020998A1 *

Also Published As

Publication number Publication date
ZA200602497B (en) 2007-09-26
WO2005020998A1 (fr) 2005-03-10

Similar Documents

Publication Publication Date Title
ZA200602497B (en) Pharmaceutical compositions of moxifloxacin and processes for their preparation
JP4463875B2 (ja) 医薬組成物
KR101840182B1 (ko) 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일]-1ｈ-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물
EP3409272B1 (fr) Composition pharmaceutique comprenant de l'eltrombopag olamine, du sucre réducteur et un liant polymérique
WO2018197088A1 (fr) Composition pharmaceutique de comprimés comprenant de l'eltrombopag olamine
GB2414668A (en) Sustained release delivery system for tetracycline compounds
CZ291999B6 (cs) Tableta pro léčbu migrény a způsob její přípravy
EP1165065B1 (fr) Comprimes a avaler a teneur elevee en n-acetylcysteine
WO2005060941A1 (fr) Composition antibiotique a liberation prolongee
CZ124497A3 (en) Oral preparations with prolonged release of cisaprid
WO2022153330A1 (fr) Compositions pharmaceutiques comprenant de l'acalabrutinib
AU2005235237A1 (en) Clarithromycin extended release formulation
US20110223245A1 (en) Controlled-release formulations of pramipexole
US20110262540A1 (en) Solid Pharmaceutical Composition Comprising Exemestane
US20080260785A1 (en) Paroxetine compositions
US20060030581A1 (en) Mannitol formulation for integrin receptor antagonist
JP6123795B2 (ja) 放出制御医薬組成物
WO2011086577A2 (fr) Composition pharmaceutique de moxifloxacine et ses sels pharmaceutiquement acceptables
JP2020090484A (ja) エルロチニブを有効成分とする医薬錠剤
JPH092953A (ja) バルフロキサシン製剤
EP2233131A1 (fr) Composition pharmaceutique contenant de la lévodopa, un inhibiteur de la catéchol-O-méthyl-transférase et de la carbidopa
WO2023232215A1 (fr) Composition pharmaceutique améliorée contenant du tadalafil et son procédé de préparation
WO2017114597A1 (fr) Formes pharmaceutiques comprenant du ((cis)-n-(4-(diméthylamino) -1,4-diphénylcyclohexyl)-n-méthylcinnamamide
EP2227224A2 (fr) Composition pharmaceutique améliorée contenant un agoniste dopaminergique non ergoté et procédé de préparation de celle-ci

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060403

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20060911

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070123